Clinical and regulatory intelligence for Congenital Disorders of Glycosylation with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

Safety →

Relevant companies

DHDDS-CDG →

Recent signals(1)

ClinicalJune 23, 2026

Safety and Tolerability Study of NMN in DHDDS-CDG Patients Initiated

A clinical trial has been initiated to assess the safety and tolerability of NMN in patients with DHDDS-CDG.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Congenital Disorders of Glycosylation →

Genetic Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.